

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# **FOSUN PHARMA**

## **复星医药**

上海復星醫藥(集團)股份有限公司

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

(Stock Code: 02196)

### **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Approval for Drug Registration of a Subsidiary” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\***

**Wu Yifang**

*Chairman*

Shanghai, the PRC

27 June 2024

*As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.*

\* *for identification purposes only*

# Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* Announcement in Relation to the Approval for Drug Registration of a Subsidiary

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

## I. Overview

Recently, the drug registration application of Nicorandil for Injection (the “**New Drug**”) self-developed by Yaopharma Co.,Ltd.\* (重慶藥友製藥有限責任公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\* (the “**Company**” and, together with its subsidiaries/units, the “**Group**”, the same applies below), which is used for the treatment of unstable angina pectoris, has received marketing registration approval from the National Medical Products Administration.

## II. General Information of the New Drug

Generic Name: Nicorandil for Injection

Dosage Form: Injection

Specification: 12 mg

Registration Category: Chemicals Category 3

Marketing Authorization Holder/Pharmaceutical Manufacturer: Yaopharma Co.,Ltd.\*  
(重慶藥友製藥有限責任公司)

Drug Approval Number: GUO YAO ZHUN ZI H20244068

### **III. Research and Marketing Progress of the New Drug**

The New Drug is a chemical drug self-developed by the Group. It is intended to be used primarily for the treatment of unstable angina pectoris.

As of May 2024, the Group has invested approximately RMB4.46 million (unaudited) in total in the research and development of the New Drug at current stage.

As at the date of this announcement, except for the New Drug, other Nicorandil for Injections that have been approved to be launched in China (hereinafter excluding Hong Kong, Macau and Taiwan for the purpose of this announcement) mainly include Nicorandil for Injections of Beijing Sihuan Kebao Pharmaceutical Co., Ltd.\* (北京四環科寶製藥股份有限公司), Yangzijiang Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd.\* (揚子江藥業集團北京海燕藥業有限公司), etc. According to the latest data from IQVIA CHPA<sup>1</sup>, the sales of Nicorandil for Injection in China in 2023 were approximately RMB785 million.

### **IV. Impact on the Listed Company and Risk Warning**

The approval for marketing registration of the New Drug will bring more options for the medication for patients with angina pectoris and will further enrich the Group's product lines. It is expected that the approval of the New Drug will not have a material impact on the Group's results at this stage.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of pharmaceutical products after launch may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.\*

27 June 2024

\* For identification purpose only

---

<sup>1</sup> Provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data represents the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.